Startup profile · funding coverage
Latent Health funding, valuation and investors
Clinical AI platform accelerating medication access via prior auth and pharmacy workflows.
Keep track of Latent Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$80M · March 2026
Latest known valuation
~$600M
Series A · March 2026
Total disclosed equity funding
$80M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · San Francisco, CA
Investors in latest funding
Lead: Spark Capital
Overview
Latent Health (Latent) builds a Clinical Reasoning Engine that automates prior authorizations, appeals, 340B compliance, and pharmacy workflows inside EHRs. Founded in 2022 by Sriram Somasundaram and Rishabh Jain, the San Francisco company raised $80M Series A in March 2026 co-led by Spark Capital and Transformation Capital at roughly $600M valuation with Conviction, McKesson Ventures, General Catalyst, and Y Combinator participating. Latent serves 45+ health systems and 2M+ patients annually per company press.
Why Latent Health is interesting
Diagnosis without therapy is failure — Latent automates the paperwork wall between doctor orders and pharmacy fulfillment, where health systems already lose margin.
Product & use cases
Enterprise pharmacy intelligence platform with agentic engine reading charts, payer policies, and pharmacy ops to approve therapies faster.
- Prior authorization automation inside Epic/Cerner
- 340B eligibility auditing in real time
- Appeals drafting with chart citations
Key facts
- Series A (Mar 2026): $80M co-led by Spark at ~$600M valuation
- 45+ health systems; 2M+ patients annually cited
- Customers include Yale New Haven, Mount Sinai, UCSF, UCLA
- Founded Nov 2022; YC alumni
Funding history (newest first)
Series A
2026-03 $80M Valuation: ~$600MSource: https://latenthealth.com/blog/latent-raises-80m-to-close-the-gap-between-diagnosis-and-treatment
Investors in our directory
Funds linked from Latent Health's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: 50% of top 20 U.S. health systems as customers per launch press — rare enterprise penetration for Series A clinical AI.
Medication access AI must be auditable and EHR-native — Latent's health system logos create moat. Risk is payer policy changes and EHR vendor bundling.
-
Notable Health adjacent
Administrative automation including prior auth.
-
Infinitus / voice AI prior auth adjacent
Phone-based payer calls versus chart-native reasoning.
-
Manual pharmacy staff incumbent
Health system backlogs Latent replaces.
Notable stories
- Forbes profiled Latent as closing the gap between diagnosis and treatment with AI agents handling prior auth paperwork.
- Company claims 30%+ reduction in medication denials per job postings.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Latent Health's financing or category context.
FAQs about Latent Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.